世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

幹細胞治療の市場：タイプ（同種、自家）、細胞源（脂肪組織由来MSC、骨髄、胎盤/臍帯）、治療用途（筋骨格系、創傷、外科手術、循環器、神経）-2027年までの世界市場予測


Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027

世界の幹細胞治療市場は、2022年の2億5700万米ドルから2027年には5億5800万米ドルに達すると予測され、予測期間中のCAGRは16.8%となる見込みです。幹細胞治療に関する臨床試験の実施件数が増加していることから、... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年9月2日 US$4,950
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		160 198 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界の幹細胞治療市場は、2022年の2億5700万米ドルから2027年には5億5800万米ドルに達すると予測され、予測期間中のCAGRは16.8%となる見込みです。幹細胞治療に関する臨床試験の実施件数が増加していることから、複数の企業が再生医療の開発に注力しています。臨床試験数の増加は、細胞ベースの治療法の研究開発に対する政府および官民の投資の増加、支持的な規制の枠組み、再生医療の研究開発におけるFDAによる承認の迅速化規定が主な要因となっている。

"幹細胞治療市場において、予測期間中、同種幹細胞治療分野がタイプ別に最も高い成長率を占めた"
幹細胞治療市場は、同種幹細胞治療と自家幹細胞治療に分類されます。同種幹細胞療法分野は、幹細胞療法市場で最大のシェアを占めています。同種幹細胞療法に使用される幹細胞は、対象となる患者以外のソースから入手され、通常はドナーから入手されます。同系統の幹細胞治療では、1つの細胞源から多くの投与量を生み出すことができるため、同系統の治療は経済的に実行可能であり、時間もかからない。さらに、同種療法は自家療法に比べ、生産プロセスのスケールアップが容易である。現在、10種類以上の同種異系幹細胞治療が承認され、世界的に利用されています。

"骨髄由来MSCsセグメントが最も高いCAGRを占めた"
世界の幹細胞治療市場は、細胞源に基づき、脂肪組織由来MSC（間葉系幹細胞）、骨髄由来MSC、胎盤・へその緒由来MSC、その他の細胞源に区分されます。骨髄由来間葉系幹細胞は、幹細胞治療において最も好まれるタイプである。骨髄由来間葉系幹細胞は容易に入手でき、試験管内での処理も少なくて済み、自家および同種幹細胞治療に使用することが可能である。過去10年間、幹細胞治療市場は、免疫不全症候群、ヘモグロビン異常症、代謝障害などの様々な治療用途に、骨髄由来の幹細胞ベースの製品への高い需要があることを目の当たりにしてきました。このことが、この分野の成長に大きく寄与しています。

"アジア太平洋地域幹細胞治療市場において最も成長率の高い国"
幹細胞治療市場は、北米、欧州、アジア太平洋、RoWに区分されます。アジア太平洋地域の幹細胞治療市場は、予測期間中に最も高いCAGRで成長すると予想されます。インドでは神経変性疾患の患者が増加していることが幹細胞治療製品の市場成長を牽引し、韓国では幹細胞治療製品に対する政府の支援がアジア太平洋地域の幹細胞治療市場の成長を後押ししています。

本レポートのために実施した主なインタビューは以下のように分類されます。

- 回答者別回答者別：供給側80％、需要側20
- 職位別Cレベル：25％、Dレベル：20％、その他：55
- 地域別北米：50％、欧州：20％、アジア太平洋：20％、RoW：10
報告書に掲載された企業リスト
- Smith+Nephew (イギリス)
- メディポスト（英国Ltd.(韓国)
- Anterogen Co.Ltd.(韓国)
- CORESTEM（韓国）
- Pharmicell Co.Ltd.(韓国)
- NuVasive Inc.（米国）
- RTI Surgical（米国）
- アロソース社（米国）
- JCRファーマシューティカルズ（株Ltd.日本
- 武田薬品工業株式会社（日本）
- Holostem Terapie Avanzate Srl（イタリア）
- オーソフィックス社（米国）
- リグロウ・バイオサイエンシズ社（インド(インド)
- STEMPEUTICS RESEARCH PVT LTD.(インド)
- Athersys（米国）
- メソブラスト社（豪州）
- バイオレストラティブ・セラピィズ社（米国）
- Pluristem Inc.（イスラエル）
- ブレインストーム・セル・リミテッド(米国)
- ビアサイト社（米国）
- ガミダセル（米国）
- Kangstem Biotech（韓国）
- ホープ・バイオサイエンシズ（米）
- セルラーバイオメディシン・グループ（米国）
- パーソナライズド幹細胞（米国）

調査対象
本レポートは、幹細胞治療市場の詳細な実態を明らかにするものです。タイプ、治療用途、地域などの異なるセグメントにおける市場規模や今後の成長性を推定することを目的としています。また、主要な市場プレイヤーの企業プロファイル、最近の開発状況、主要な市場戦略とともに、詳細な競合分析も行っています。

レポート購入の主なメリット
本レポートは、幹細胞治療市場全体とそのセグメントにおける収益数の最も近い概算を提供することで、市場リーダーや新規参入者の助けとなります。また、利害関係者が競争環境をより良く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得ることができます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、動向、機会、課題に関する情報を提供することを可能にします。

ページTOPに戻る


目次

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS 26
1.3 STUDY SCOPE 27
FIGURE 1 STEM CELL THERAPY MARKET 27
1.3.1 YEARS CONSIDERED 27
1.4 CURRENCY CONSIDERED 28
1.5 LIMITATIONS 28
1.6 STAKEHOLDERS 28
1.7 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH APPROACH 30
FIGURE 2 RESEARCH DESIGN 30
2.1.1 SECONDARY DATA 31
2.1.2 PRIMARY DATA 32
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: STEM CELL THERAPY MARKET 32
2.2 MARKET SIZE ESTIMATION 33
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF STEM CELL THERAPY MARKET PLAYERS 33
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021 34
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021 34
2.3 GROWTH FORECAST 36
FIGURE 7 STEM CELL THERAPY MARKET: CAGR PROJECTIONS (2022–2027) 36
FIGURE 8 STEM CELL THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 37
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 37
2.4 DATA TRIANGULATION 39
FIGURE 10 DATA TRIANGULATION METHODOLOGY 39
2.5 PRIMARY INSIGHTS 40
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 40
2.6 RESEARCH ASSUMPTIONS 40
2.7 RISK ASSESSMENT 41
 
3 EXECUTIVE SUMMARY 42
FIGURE 12 STEM CELL THERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 42
FIGURE 13 STEM CELL THERAPY MARKET, BY CELL SOURCE,
2022 VS. 2027 (USD MILLION) 43
FIGURE 14 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2022 VS. 2026 (USD MILLION) 43
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF STEM CELL THERAPY MARKET 44
4 PREMIUM INSIGHTS 46
4.1 STEM CELL THERAPY MARKET OVERVIEW 46
FIGURE 16 INCREASING INVESTMENTS & FUNDING INITIATIVES FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH 46
4.2 NORTH AMERICA: STEM CELL THERAPY MARKET 47
FIGURE 17 ALLOGENEIC STEM CELL THERAPY TO COMMAND LARGEST SHARE IN 2021 47
4.3 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2022 VS. 2027 (USD MILLION) 47
FIGURE 18 BONE MARROW-DERIVED MSCS TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
FIGURE 19 MARKET DYNAMICS: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES 48
5.2 MARKET DYNAMICS 49
5.2.1 DRIVERS 49
5.2.1.1 Availability of funding for stem cell research 49
TABLE 1 ICMR FUNDING FOR STEM CELL RESEARCH, 2019–2021 (USD) 49
FIGURE 20 STEM CELL RESEARCH FUNDING IN LAST 10 YEARS 49
TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION) 50
5.2.1.2 Increasing GMP certification approvals for cell therapy production facilities 50
TABLE 3 NEW GMP FACILITIES, 2017-2020 51
5.2.1.3 Increasing clinical trials for stem cell-based therapies 51
FIGURE 21 NUMBER OF CLINICAL TRIALS (2015-2020) 51
FIGURE 22 CLINICAL TRIALS, BY PHASE 52
5.2.2 RESTRAINTS 52
5.2.2.1 Ethical concerns related to embryonic stem cells 52
5.2.2.2 High cost of cell-based research 52
5.2.3 OPPORTUNITIES 53
5.2.3.1 Emergence of iPSCs as an alternative to ESCs 53
5.2.3.2 Growing demand for cell & gene therapies 53
5.2.4 CHALLENGES 53
5.2.4.1 Technical limitations associated with manufacturing processes 53
 
5.3 TECHNOLOGY ANALYSIS 54
TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES 54
5.4 VALUE CHAIN ANALYSIS 54
FIGURE 23 VALUE CHAIN ANALYSIS OF STEM CELL THERAPY MARKET 55
5.5 ROLE IN ECOSYSTEM 56
FIGURE 24 ECOSYSTEM MARKET MAP 56
5.6 SUPPLY CHAIN ANALYSIS 56
FIGURE 25 SUPPLY CHAIN ANALYSIS OF STEM CELL THERAPY MARKET 57
TABLE 5 SUPPLY CHAIN ANALYSIS: COMMERCIAL SCALE/KEY MANUFACTURERS 57
TABLE 6 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS 58
5.7 PORTER’S FIVE FORCES ANALYSIS 58
5.7.1 THREAT OF NEW ENTRANTS 59
5.7.2 THREAT OF SUBSTITUTES 59
5.7.3 BARGAINING POWER OF SUPPLIERS 59
5.7.4 BARGAINING POWER OF BUYERS 59
5.7.5 INTENSITY OF COMPETITION RIVALRY 60
5.8 REGULATORY LANDSCAPE 60
5.8.1 NORTH AMERICA 60
TABLE 7 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 60
5.8.2 EUROPE 62
TABLE 8 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 62
5.8.3 ASIA PACIFIC 63
TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 63
5.8.4 REST OF THE WORLD 65
TABLE 10 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 65
5.9 PRICING ANALYSIS 66
5.9.1 PRICING ANALYSIS 66
TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS 66
5.9.2 AVERAGE SELLING PRICE TREND – STEM CELL THERAPY TREATMENT 66
5.10 PATENT ANALYSIS 67
FIGURE 26 PATENT ANALYSIS OF STEM CELL THERAPIES IN LAST 10 YEARS (2011-2020) 67
5.11 KEY CONFERENCES & EVENTS IN 2022–2023 67
5.11.1 STEM CELL THERAPY CONFERENCES (2022–2023) 67
TABLE 12 STEM CELL THERAPY CONFERENCES (2022–2023) 67
5.12 DISRUPTIONS & TRENDS IMPACTING CUSTOMERS’ BUSINESSES 68
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 68
FIGURE 27 KEY STAKEHOLDERS IN STEM CELL THERAPY MARKET 68
FIGURE 28 KEY BUYING CRITERIA FOR END USERS 69
FIGURE 29 REVENUE SHIFT & NEW POCKET FOR STEM CELL THERAPY COMPANIES 69
 
6 STEM CELL THERAPY MARKET, BY TYPE 70
6.1 INTRODUCTION 71
TABLE 13 STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 71
6.2 ALLOGENEIC STEM CELL THERAPY 71
6.2.1 FAVORABLE SCALING UP OF PRODUCTION PROCESSES TO DRIVE SEGMENT 71
TABLE 14 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION,
2020–2027 (USD MILLION) 71
TABLE 15 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 16 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 17 ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
6.3 AUTOLOGOUS STEM CELL THERAPY 73
6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE SEGMENT 73
TABLE 18 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION,
2020–2027 (USD MILLION) 73
TABLE 19 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 20 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 74
TABLE 21 ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
7 STEM CELL THERAPY MARKET, BY CELL SOURCE 75
7.1 INTRODUCTION 76
TABLE 22 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 76
7.2 ADIPOSE TISSUE-DERIVED MSCS 76
7.2.1 PROPERTIES SUCH AS SIMPLIFIED HARVESTING & EASE OF ISOLATION TO DRIVE MARKET 76
TABLE 23 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 24 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 25 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 26 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 78
7.3 BONE MARROW-DERIVED MSCS 78
7.3.1 HIGH PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET 78
TABLE 27 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 28 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 29 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 30 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 80
7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS 80
7.4.1 LOWER CHANCES OF IMMUNE REJECTION TO SUPPORT MARKET 80
TABLE 31 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 80
TABLE 32 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 33 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 34 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
7.5 OTHER CELL SOURCES 82
TABLE 35 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2020–2027 (USD MILLION) 82
TABLE 36 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 37 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 38 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2020–2027 (USD MILLION) 83
8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION 84
8.1 INTRODUCTION 85
TABLE 39 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 85
8.2 MUSCULOSKELETAL DISORDERS 85
8.2.1 RISING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET 85
TABLE 40 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2020–2027 (USD MILLION) 86
TABLE 41 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 42 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 43 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 87
8.3 WOUNDS & INJURIES 87
8.3.1 GROWING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH 87
TABLE 44 STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY REGION, 2020–2027 (USD MILLION) 87
TABLE 45 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 46 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 47 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY COUNTRY, 2020–2027 (USD MILLION) 88
 
8.4 INFLAMMATORY & AUTOIMMUNE DISEASES 89
8.4.1 INCREASING CLINICAL TRIALS FOR BONE MARROW-DERIVED MSCS TO SUPPORT MARKET GROWTH 89
TABLE 48 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 49 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 50 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 51 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & INFLAMMATORY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 90
8.5 SURGERIES 91
8.5.1 GROWING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH 91
TABLE 52 STEM CELL THERAPY MARKET FOR SURGERIES, BY REGION,
2020–2027 (USD MILLION) 91
TABLE 53 NORTH AMERICA: STEM CELL THERAPY MARKET FOR SURGERIES,
BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 54 EUROPE: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 55 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION) 92
8.6 CARDIOVASCULAR DISEASES 92
8.6.1 RISING DEMAND FOR CVD TREATMENTS TO SUPPORT MARKET GROWTH 92
TABLE 56 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 57 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 58 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 59 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 94
8.7 NEUROLOGICAL DISORDERS 94
8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS TO SUPPORT MARKET GROWTH 94
TABLE 60 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 94
TABLE 61 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 62 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 63 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 95
8.8 OTHER THERAPEUTIC APPLICATIONS 96
TABLE 64 STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 66 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 67 ASIA PACIFIC: STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
9 STEM CELL THERAPY MARKET, BY REGION 98
9.1 INTRODUCTION 99
TABLE 68 STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 99
9.2 NORTH AMERICA 99
FIGURE 30 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT 100
TABLE 69 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 100
TABLE 70 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 101
TABLE 71 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 101
TABLE 72 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 101
9.2.1 US 102
9.2.1.1 Rising approvals for stem cell therapy products to drive market 102
FIGURE 31 NIH FUNDING IN LAST 10 YEARS (2011–2021) 102
TABLE 73 US: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 102
TABLE 74 US: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 75 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 103
9.2.2 CANADA 103
9.2.2.1 Increasing government focus on targeted stem cell therapy treatment to drive market 103
TABLE 76 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 104
TABLE 77 CANADA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 104
TABLE 78 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 105
9.3 EUROPE 105
TABLE 79 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 105
TABLE 80 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 106
TABLE 81 EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 106
TABLE 82 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 106
9.3.1 GERMANY 107
9.3.1.1 Strong R&D base and growing focus on minimally invasive treatments to drive market 107
TABLE 83 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 107
TABLE 84 GERMANY: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 107
TABLE 85 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 108
9.3.2 UK 108
9.3.2.1 Rising adoption of cell-based therapies to drive market 108
TABLE 86 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 109
TABLE 87 UK: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 88 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 109
9.3.3 FRANCE 110
9.3.3.1 Rising healthcare expenditure to support uptake of stem cell therapy products 110
TABLE 89 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 110
TABLE 90 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 91 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 111
9.3.4 REST OF EUROPE 111
TABLE 92 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 111
TABLE 93 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 112
TABLE 94 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 112
9.4 ASIA PACIFIC 113
FIGURE 32 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT 113
TABLE 95 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 114
TABLE 96 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 97 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 114
9.4.1 JAPAN 115
9.4.1.1 Growing geriatric population and rapid regulatory processes to drive market 115
TABLE 98 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 115
TABLE 99 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 100 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 116
9.4.2 SOUTH KOREA 116
9.4.2.1 Favorable government support for stem cell therapy products to support market growth 116
TABLE 101 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 116
TABLE 102 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 117
TABLE 103 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 117
9.4.3 INDIA 117
9.4.3.1 Rising cases of neurodegenerative disorders drive market 117
TABLE 104 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 118
TABLE 105 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 106 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 118
9.4.4 REST OF ASIA PACIFIC 119
TABLE 107 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 119
TABLE 108 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 119
TABLE 109 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 120
9.5 REST OF THE WORLD 120
TABLE 110 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 121
TABLE 111 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 121
TABLE 112 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 121
10 COMPETITIVE LANDSCAPE 122
10.1 INTRODUCTION 122
10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 122
FIGURE 33 STEM CELL THERAPY MARKET: STRATEGIES ADOPTED 123
10.3 REVENUE SHARE ANALYSIS 123
10.4 MARKET SHARE ANALYSIS (2021) 124
10.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS) 125
10.5.1 STARS 126
10.5.2 EMERGING LEADERS 126
10.5.3 PERVASIVE PLAYERS 126
10.5.4 PARTICIPANTS 126
FIGURE 36 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR APPROVED PRODUCTS (2021) 127
10.6 COMPETITIVE BENCHMARKING 128
10.6.1 STEM CELL THERAPY MARKET: A DETAILED LIST OF STARTUPS/SMES 128
TABLE 113 STEM CELL THERAPY MARKET: DETAILED LIST OF STARTUPS/SMES 128
10.6.2 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES) 129
TABLE 114 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES] 129
10.7 COMPANY EVALUATION QUADRANT (SMES/START-UPS) 130
10.7.1 PROGRESSIVE COMPANIES 130
10.7.2 STARTING BLOCKS 130
10.7.3 RESPONSIVE COMPANIES 130
10.7.4 DYNAMIC COMPANIES 130
FIGURE 37 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR PRODUCTS UNDER PIPELINE (2021) 131
10.8 COMPANY PRODUCT FOOTPRINT ANALYSIS 132
TABLE 115 COMPANY PRODUCT FOOTPRINT 132
10.9 COMPANY FOOTPRINT OF MAJOR PLAYERS 133
TABLE 116 COMPANY REGIONAL FOOTPRINT 133
10.10 COMPETITIVE SCENARIO 134
TABLE 117 STEM CELL THERAPY MARKET: REGULATORY APPROVALS 134
TABLE 118 STEM CELL THERAPY MARKET: DEALS 134
11 COMPANY PROFILES 135
11.1 MAJOR PLAYERS 135
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 SMITH+NEPHEW 135
TABLE 119 SMITH+NEPHEW: BUSINESS OVERVIEW 135
FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2021) 136
TABLE 120 SMITH+NEPHEW: PRODUCT OFFERINGS 136
TABLE 121 SMITH+NEPHEW: DEALS 137
11.1.2 MEDIPOST CO., LTD. 138
TABLE 122 MEDIPOST CO., LTD: BUSINESS OVERVIEW 138
FIGURE 39 MEDIPOST CO., LTD: COMPANY SNAPSHOT (2019) 138
TABLE 123 MEDIPOST CO., LTD: PRODUCT OFFERINGS 139
TABLE 124 MEDIPOST CO., LTD: PRODUCT APPROVALS 139
TABLE 125 MEDIPOST CO., LTD: DEALS 139
TABLE 126 MEDIPOST CO., LTD: OTHERS 139
TABLE 127 MEDIPOST CO., LTD: REGULATORY APPROVALS AND PATENTS 140
11.1.3 JCR PHARMACEUTICALS CO., LTD. 141
TABLE 128 JCR PHARMACEUTICALS CO., LTD: BUSINESS OVERVIEW 141
FIGURE 40 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2021) 141
TABLE 129 JCR PHARMACEUTICALS CO., LTD: PRODUCT OFFERINGS 142
11.1.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED 143
TABLE 130 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW 143
FIGURE 41 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021) 143
TABLE 131 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT OFFERINGS 144
TABLE 132 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS 144
TABLE 133 TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGULATORY APPROVALS 144
11.1.5 ANTEROGEN. CO., LTD. 145
TABLE 134 ANTEROGEN CO., LTD: BUSINESS OVERVIEW 145
TABLE 135 ANTEROGEN CO., LTD: PRODUCT OFFERINGS 145
11.1.6 CORESTEM 146
TABLE 136 CORESTEM: BUSINESS OVERVIEW 146
TABLE 137 CORESTEM: PRODUCT OFFERINGS 146
TABLE 138 CORESTEM: REGULATORY APPROVALS 146
11.1.7 PHARMICELL CO., LTD. 147
TABLE 139 PHARMICELL CO., LTD.: BUSINESS OVERVIEW 147
TABLE 140 PHARMICELL CO., LTD.: PRODUCT OFFERINGS 147
TABLE 141 PHARMICELL CO., LTD.: DEALS 147
11.1.8 NUVASIVE, INC. 148
TABLE 142 NUVASIVE, INC: BUSINESS OVERVIEW 148
FIGURE 42 NUVASIVE, INC: COMPANY SNAPSHOT (2021) 149
TABLE 143 NUVASIVE, INC.: PRODUCT OFFERINGS 149
11.1.9 RTI SURGICAL 150
TABLE 144 RTI SURGICAL: BUSINESS OVERVIEW 150
TABLE 145 RTI SURGICAL: PRODUCT OFFERINGS 150
11.1.10 ALLOSOURCE 151
TABLE 146 ALLOSOURCE: BUSINESS OVERVIEW 151
TABLE 147 ALLOSOURCE: PRODUCT OFFERINGS 151
11.1.11 HOLOSTEM TERAPIE AVANZATE SRL 152
TABLE 148 HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW 152
TABLE 149 HOLOSTEM TERAPIE AVANZATE SRL: PRODUCT OFFERINGS 152
11.1.12 ORTHOFIX 153
TABLE 150 ORTHOFIX: BUSINESS OVERVIEW 153
FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2021) 154
TABLE 151 ORTHOFIX: PRODUCT OFFERINGS 154
11.1.13 STEMPEUTICS RESEARCH 155
TABLE 152 STEMPEUTICS RESEARCH: BUSINESS OVERVIEW 155
TABLE 153 STEMPEUTICS RESEARCH: PRODUCT OFFERINGS 155
11.1.14 REGROW BIOSCIENCES PVT LTD. 156
TABLE 154 REGROW BIOSCIENCES PVT LTD: BUSINESS OVERVIEW 156
TABLE 155 REGROW BIOSCIENCES PVT LTD: PRODUCT OFFERINGS 156
11.2 OTHER PLAYERS (PRODUCTS IN PIPELINE) 157
11.2.1 ATHERSYS, INC. 157
11.2.2 MESOBLAST LTD 157
11.2.3 BIORESTORATIVE THERAPIES, INC. 158
11.2.4 PLURISTEM INC. 158
11.2.5 BRAINSTORM CELL LIMITED. 158
11.2.6 GAMIDA CELL 159
11.2.7 VIACYTE, INC. 159
11.2.8 KANGSTEM BIOTECH 159
11.2.9 HOPE BIOSCIENCES 160
11.2.10 CELLULAR BIOMEDICINE GROUP (CBMG) 160
11.2.11 PERSONALIZED STEM CELLS 160
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 161
12.1 DISCUSSION GUIDE 161
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 163
12.3 CUSTOMIZATION OPTIONS 165
12.4 RELATED REPORTS 165
12.5 AUTHOR DETAILS 166

　

ページTOPに戻る


　

Summary

The global stem cell therapy market is projected to reach USD 558 million by 2027 from USD 257 million in 2022, at a CAGR of 16.8% during the forecast period. Several companies are focusing on developing regenerative medicine due to the rising number of clinical trials conducted on stem cell therapies. The increasing number of clinical trials has largely taken place owing to the rising government and public & private investments for R&D in cell-based therapies, supportive regulatory framework, and accelerated approval provisions by the FDA in regenerative medicine R&D.

“The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, by type, during the forecast period”
The stem cell therapy market is segmented into allogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. Stem cells used for allogeneic stem cell therapy are obtained from sources other than the target patient, which is usually from a donor. In allogeneic stem cell therapy, one cell source can produce many doses, thus making allogeneic therapy economically viable and less time-consuming. Moreover, it is easier to scale up production processes for allogeneic therapy than for autologous therapy. Currently, more than ten approved commercialized allogeneic stem cell therapies are available globally.

“Bone Marrow-derived MSCs segment accounted for the highest CAGR”
Based on the cell source the global stem cell therapy market is segmented into adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources. Bone marrow-derived mesenchymal stem cells are the most preferred type for stem cell therapies. Bone marrow MSCs are readily available, require less in vitro processing, and can be used for autologous and allogeneic stem cell therapy. Over the last decade, the stem cell therapy market has witnessed high demand for several bone marrow-derived stem cell-based products for various therapeutic applications, including immune-deficiency syndromes, hemoglobinopathies, and metabolic disorders. This has collectively contributed the segment’s growth.

“Asia Pacific: The fastest-growing country in the stem cell therapy market”
The stem cell therapy market is segmented into North America, Europe, Asia Pacific, RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. Rising cases of neurodegenerative disorders drive market growth for stem cell therapy products in India along with favorable government support for stem cell therapy products in South Korea have propelled the growth of Asia Pacific stem cell therapy market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: C-level - 25%, D-level - 20%, and Others - 55%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
Lists of Companies Profiled in the Report:
• Smith+Nephew (UK)
• MEDIPOST Co. Ltd. (South Korea)
• Anterogen Co. Ltd. (South Korea)
• CORESTEM (South Korea)
• Pharmicell Co. Ltd. (South Korea)
• NuVasive Inc. (US)
• RTI Surgical (US)
• AlloSource (US)
• JCR Pharmaceuticals Co. Ltd. (Japan)
• Takeda Pharmaceutical Company Limited (Japan)
• Holostem Terapie Avanzate Srl (Italy)
• Orthofix (US)
• Regrow Biosciences Pvt Ltd. (India)
• STEMPEUTICS RESEARCH PVT LTD. (India)
• Athersys (US)
• Mesoblast Ltd (Australia)
• Biorestorative Therapies Inc. (US)
• Pluristem Inc. (Israel)
• Brainstorm Cell Limited. (US)
• ViaCyte Inc. (US)
• Gamida Cell (US)
• Kangstem Biotech (South Korea)
• Hope Biosciences (US)
• Cellular Biomedicine Group (US)
• Personalized Stem Cells (US)

Research Coverage:
This report provides a detailed picture of the stem cell therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, therapeutic applications, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS 26
1.3 STUDY SCOPE 27
FIGURE 1 STEM CELL THERAPY MARKET 27
1.3.1 YEARS CONSIDERED 27
1.4 CURRENCY CONSIDERED 28
1.5 LIMITATIONS 28
1.6 STAKEHOLDERS 28
1.7 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH APPROACH 30
FIGURE 2 RESEARCH DESIGN 30
2.1.1 SECONDARY DATA 31
2.1.2 PRIMARY DATA 32
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: STEM CELL THERAPY MARKET 32
2.2 MARKET SIZE ESTIMATION 33
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF STEM CELL THERAPY MARKET PLAYERS 33
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021 34
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021 34
2.3 GROWTH FORECAST 36
FIGURE 7 STEM CELL THERAPY MARKET: CAGR PROJECTIONS (2022–2027) 36
FIGURE 8 STEM CELL THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 37
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 37
2.4 DATA TRIANGULATION 39
FIGURE 10 DATA TRIANGULATION METHODOLOGY 39
2.5 PRIMARY INSIGHTS 40
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 40
2.6 RESEARCH ASSUMPTIONS 40
2.7 RISK ASSESSMENT 41
 
3 EXECUTIVE SUMMARY 42
FIGURE 12 STEM CELL THERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 42
FIGURE 13 STEM CELL THERAPY MARKET, BY CELL SOURCE,
2022 VS. 2027 (USD MILLION) 43
FIGURE 14 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2022 VS. 2026 (USD MILLION) 43
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF STEM CELL THERAPY MARKET 44
4 PREMIUM INSIGHTS 46
4.1 STEM CELL THERAPY MARKET OVERVIEW 46
FIGURE 16 INCREASING INVESTMENTS & FUNDING INITIATIVES FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH 46
4.2 NORTH AMERICA: STEM CELL THERAPY MARKET 47
FIGURE 17 ALLOGENEIC STEM CELL THERAPY TO COMMAND LARGEST SHARE IN 2021 47
4.3 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2022 VS. 2027 (USD MILLION) 47
FIGURE 18 BONE MARROW-DERIVED MSCS TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
FIGURE 19 MARKET DYNAMICS: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES 48
5.2 MARKET DYNAMICS 49
5.2.1 DRIVERS 49
5.2.1.1 Availability of funding for stem cell research 49
TABLE 1 ICMR FUNDING FOR STEM CELL RESEARCH, 2019–2021 (USD) 49
FIGURE 20 STEM CELL RESEARCH FUNDING IN LAST 10 YEARS 49
TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION) 50
5.2.1.2 Increasing GMP certification approvals for cell therapy production facilities 50
TABLE 3 NEW GMP FACILITIES, 2017-2020 51
5.2.1.3 Increasing clinical trials for stem cell-based therapies 51
FIGURE 21 NUMBER OF CLINICAL TRIALS (2015-2020) 51
FIGURE 22 CLINICAL TRIALS, BY PHASE 52
5.2.2 RESTRAINTS 52
5.2.2.1 Ethical concerns related to embryonic stem cells 52
5.2.2.2 High cost of cell-based research 52
5.2.3 OPPORTUNITIES 53
5.2.3.1 Emergence of iPSCs as an alternative to ESCs 53
5.2.3.2 Growing demand for cell & gene therapies 53
5.2.4 CHALLENGES 53
5.2.4.1 Technical limitations associated with manufacturing processes 53
 
5.3 TECHNOLOGY ANALYSIS 54
TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES 54
5.4 VALUE CHAIN ANALYSIS 54
FIGURE 23 VALUE CHAIN ANALYSIS OF STEM CELL THERAPY MARKET 55
5.5 ROLE IN ECOSYSTEM 56
FIGURE 24 ECOSYSTEM MARKET MAP 56
5.6 SUPPLY CHAIN ANALYSIS 56
FIGURE 25 SUPPLY CHAIN ANALYSIS OF STEM CELL THERAPY MARKET 57
TABLE 5 SUPPLY CHAIN ANALYSIS: COMMERCIAL SCALE/KEY MANUFACTURERS 57
TABLE 6 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS 58
5.7 PORTER’S FIVE FORCES ANALYSIS 58
5.7.1 THREAT OF NEW ENTRANTS 59
5.7.2 THREAT OF SUBSTITUTES 59
5.7.3 BARGAINING POWER OF SUPPLIERS 59
5.7.4 BARGAINING POWER OF BUYERS 59
5.7.5 INTENSITY OF COMPETITION RIVALRY 60
5.8 REGULATORY LANDSCAPE 60
5.8.1 NORTH AMERICA 60
TABLE 7 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 60
5.8.2 EUROPE 62
TABLE 8 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 62
5.8.3 ASIA PACIFIC 63
TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 63
5.8.4 REST OF THE WORLD 65
TABLE 10 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 65
5.9 PRICING ANALYSIS 66
5.9.1 PRICING ANALYSIS 66
TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS 66
5.9.2 AVERAGE SELLING PRICE TREND – STEM CELL THERAPY TREATMENT 66
5.10 PATENT ANALYSIS 67
FIGURE 26 PATENT ANALYSIS OF STEM CELL THERAPIES IN LAST 10 YEARS (2011-2020) 67
5.11 KEY CONFERENCES & EVENTS IN 2022–2023 67
5.11.1 STEM CELL THERAPY CONFERENCES (2022–2023) 67
TABLE 12 STEM CELL THERAPY CONFERENCES (2022–2023) 67
5.12 DISRUPTIONS & TRENDS IMPACTING CUSTOMERS’ BUSINESSES 68
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 68
FIGURE 27 KEY STAKEHOLDERS IN STEM CELL THERAPY MARKET 68
FIGURE 28 KEY BUYING CRITERIA FOR END USERS 69
FIGURE 29 REVENUE SHIFT & NEW POCKET FOR STEM CELL THERAPY COMPANIES 69
 
6 STEM CELL THERAPY MARKET, BY TYPE 70
6.1 INTRODUCTION 71
TABLE 13 STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 71
6.2 ALLOGENEIC STEM CELL THERAPY 71
6.2.1 FAVORABLE SCALING UP OF PRODUCTION PROCESSES TO DRIVE SEGMENT 71
TABLE 14 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION,
2020–2027 (USD MILLION) 71
TABLE 15 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 16 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 17 ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
6.3 AUTOLOGOUS STEM CELL THERAPY 73
6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE SEGMENT 73
TABLE 18 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION,
2020–2027 (USD MILLION) 73
TABLE 19 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 20 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 74
TABLE 21 ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
7 STEM CELL THERAPY MARKET, BY CELL SOURCE 75
7.1 INTRODUCTION 76
TABLE 22 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 76
7.2 ADIPOSE TISSUE-DERIVED MSCS 76
7.2.1 PROPERTIES SUCH AS SIMPLIFIED HARVESTING & EASE OF ISOLATION TO DRIVE MARKET 76
TABLE 23 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 24 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 25 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 26 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 78
7.3 BONE MARROW-DERIVED MSCS 78
7.3.1 HIGH PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET 78
TABLE 27 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 28 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 29 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 30 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 80
7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS 80
7.4.1 LOWER CHANCES OF IMMUNE REJECTION TO SUPPORT MARKET 80
TABLE 31 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 80
TABLE 32 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 33 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 34 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
7.5 OTHER CELL SOURCES 82
TABLE 35 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2020–2027 (USD MILLION) 82
TABLE 36 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 37 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 38 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2020–2027 (USD MILLION) 83
8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION 84
8.1 INTRODUCTION 85
TABLE 39 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 85
8.2 MUSCULOSKELETAL DISORDERS 85
8.2.1 RISING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET 85
TABLE 40 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2020–2027 (USD MILLION) 86
TABLE 41 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 42 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 43 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 87
8.3 WOUNDS & INJURIES 87
8.3.1 GROWING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH 87
TABLE 44 STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY REGION, 2020–2027 (USD MILLION) 87
TABLE 45 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 46 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 47 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY COUNTRY, 2020–2027 (USD MILLION) 88
 
8.4 INFLAMMATORY & AUTOIMMUNE DISEASES 89
8.4.1 INCREASING CLINICAL TRIALS FOR BONE MARROW-DERIVED MSCS TO SUPPORT MARKET GROWTH 89
TABLE 48 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 49 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 50 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 51 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & INFLAMMATORY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 90
8.5 SURGERIES 91
8.5.1 GROWING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH 91
TABLE 52 STEM CELL THERAPY MARKET FOR SURGERIES, BY REGION,
2020–2027 (USD MILLION) 91
TABLE 53 NORTH AMERICA: STEM CELL THERAPY MARKET FOR SURGERIES,
BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 54 EUROPE: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 55 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION) 92
8.6 CARDIOVASCULAR DISEASES 92
8.6.1 RISING DEMAND FOR CVD TREATMENTS TO SUPPORT MARKET GROWTH 92
TABLE 56 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 57 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 58 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 59 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 94
8.7 NEUROLOGICAL DISORDERS 94
8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS TO SUPPORT MARKET GROWTH 94
TABLE 60 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 94
TABLE 61 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 62 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 63 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 95
8.8 OTHER THERAPEUTIC APPLICATIONS 96
TABLE 64 STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 66 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 67 ASIA PACIFIC: STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
9 STEM CELL THERAPY MARKET, BY REGION 98
9.1 INTRODUCTION 99
TABLE 68 STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 99
9.2 NORTH AMERICA 99
FIGURE 30 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT 100
TABLE 69 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 100
TABLE 70 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 101
TABLE 71 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 101
TABLE 72 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 101
9.2.1 US 102
9.2.1.1 Rising approvals for stem cell therapy products to drive market 102
FIGURE 31 NIH FUNDING IN LAST 10 YEARS (2011–2021) 102
TABLE 73 US: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 102
TABLE 74 US: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 75 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 103
9.2.2 CANADA 103
9.2.2.1 Increasing government focus on targeted stem cell therapy treatment to drive market 103
TABLE 76 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 104
TABLE 77 CANADA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 104
TABLE 78 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 105
9.3 EUROPE 105
TABLE 79 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 105
TABLE 80 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 106
TABLE 81 EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 106
TABLE 82 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 106
9.3.1 GERMANY 107
9.3.1.1 Strong R&D base and growing focus on minimally invasive treatments to drive market 107
TABLE 83 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 107
TABLE 84 GERMANY: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 107
TABLE 85 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 108
9.3.2 UK 108
9.3.2.1 Rising adoption of cell-based therapies to drive market 108
TABLE 86 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 109
TABLE 87 UK: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 88 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 109
9.3.3 FRANCE 110
9.3.3.1 Rising healthcare expenditure to support uptake of stem cell therapy products 110
TABLE 89 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 110
TABLE 90 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 91 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 111
9.3.4 REST OF EUROPE 111
TABLE 92 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 111
TABLE 93 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 112
TABLE 94 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 112
9.4 ASIA PACIFIC 113
FIGURE 32 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT 113
TABLE 95 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 114
TABLE 96 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 97 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 114
9.4.1 JAPAN 115
9.4.1.1 Growing geriatric population and rapid regulatory processes to drive market 115
TABLE 98 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 115
TABLE 99 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 100 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 116
9.4.2 SOUTH KOREA 116
9.4.2.1 Favorable government support for stem cell therapy products to support market growth 116
TABLE 101 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 116
TABLE 102 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 117
TABLE 103 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 117
9.4.3 INDIA 117
9.4.3.1 Rising cases of neurodegenerative disorders drive market 117
TABLE 104 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 118
TABLE 105 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 106 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 118
9.4.4 REST OF ASIA PACIFIC 119
TABLE 107 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 119
TABLE 108 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 119
TABLE 109 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 120
9.5 REST OF THE WORLD 120
TABLE 110 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 121
TABLE 111 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 121
TABLE 112 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 121
10 COMPETITIVE LANDSCAPE 122
10.1 INTRODUCTION 122
10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 122
FIGURE 33 STEM CELL THERAPY MARKET: STRATEGIES ADOPTED 123
10.3 REVENUE SHARE ANALYSIS 123
10.4 MARKET SHARE ANALYSIS (2021) 124
10.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS) 125
10.5.1 STARS 126
10.5.2 EMERGING LEADERS 126
10.5.3 PERVASIVE PLAYERS 126
10.5.4 PARTICIPANTS 126
FIGURE 36 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR APPROVED PRODUCTS (2021) 127
10.6 COMPETITIVE BENCHMARKING 128
10.6.1 STEM CELL THERAPY MARKET: A DETAILED LIST OF STARTUPS/SMES 128
TABLE 113 STEM CELL THERAPY MARKET: DETAILED LIST OF STARTUPS/SMES 128
10.6.2 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES) 129
TABLE 114 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES] 129
10.7 COMPANY EVALUATION QUADRANT (SMES/START-UPS) 130
10.7.1 PROGRESSIVE COMPANIES 130
10.7.2 STARTING BLOCKS 130
10.7.3 RESPONSIVE COMPANIES 130
10.7.4 DYNAMIC COMPANIES 130
FIGURE 37 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR PRODUCTS UNDER PIPELINE (2021) 131
10.8 COMPANY PRODUCT FOOTPRINT ANALYSIS 132
TABLE 115 COMPANY PRODUCT FOOTPRINT 132
10.9 COMPANY FOOTPRINT OF MAJOR PLAYERS 133
TABLE 116 COMPANY REGIONAL FOOTPRINT 133
10.10 COMPETITIVE SCENARIO 134
TABLE 117 STEM CELL THERAPY MARKET: REGULATORY APPROVALS 134
TABLE 118 STEM CELL THERAPY MARKET: DEALS 134
11 COMPANY PROFILES 135
11.1 MAJOR PLAYERS 135
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 SMITH+NEPHEW 135
TABLE 119 SMITH+NEPHEW: BUSINESS OVERVIEW 135
FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2021) 136
TABLE 120 SMITH+NEPHEW: PRODUCT OFFERINGS 136
TABLE 121 SMITH+NEPHEW: DEALS 137
11.1.2 MEDIPOST CO., LTD. 138
TABLE 122 MEDIPOST CO., LTD: BUSINESS OVERVIEW 138
FIGURE 39 MEDIPOST CO., LTD: COMPANY SNAPSHOT (2019) 138
TABLE 123 MEDIPOST CO., LTD: PRODUCT OFFERINGS 139
TABLE 124 MEDIPOST CO., LTD: PRODUCT APPROVALS 139
TABLE 125 MEDIPOST CO., LTD: DEALS 139
TABLE 126 MEDIPOST CO., LTD: OTHERS 139
TABLE 127 MEDIPOST CO., LTD: REGULATORY APPROVALS AND PATENTS 140
11.1.3 JCR PHARMACEUTICALS CO., LTD. 141
TABLE 128 JCR PHARMACEUTICALS CO., LTD: BUSINESS OVERVIEW 141
FIGURE 40 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2021) 141
TABLE 129 JCR PHARMACEUTICALS CO., LTD: PRODUCT OFFERINGS 142
11.1.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED 143
TABLE 130 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW 143
FIGURE 41 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021) 143
TABLE 131 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT OFFERINGS 144
TABLE 132 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS 144
TABLE 133 TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGULATORY APPROVALS 144
11.1.5 ANTEROGEN. CO., LTD. 145
TABLE 134 ANTEROGEN CO., LTD: BUSINESS OVERVIEW 145
TABLE 135 ANTEROGEN CO., LTD: PRODUCT OFFERINGS 145
11.1.6 CORESTEM 146
TABLE 136 CORESTEM: BUSINESS OVERVIEW 146
TABLE 137 CORESTEM: PRODUCT OFFERINGS 146
TABLE 138 CORESTEM: REGULATORY APPROVALS 146
11.1.7 PHARMICELL CO., LTD. 147
TABLE 139 PHARMICELL CO., LTD.: BUSINESS OVERVIEW 147
TABLE 140 PHARMICELL CO., LTD.: PRODUCT OFFERINGS 147
TABLE 141 PHARMICELL CO., LTD.: DEALS 147
11.1.8 NUVASIVE, INC. 148
TABLE 142 NUVASIVE, INC: BUSINESS OVERVIEW 148
FIGURE 42 NUVASIVE, INC: COMPANY SNAPSHOT (2021) 149
TABLE 143 NUVASIVE, INC.: PRODUCT OFFERINGS 149
11.1.9 RTI SURGICAL 150
TABLE 144 RTI SURGICAL: BUSINESS OVERVIEW 150
TABLE 145 RTI SURGICAL: PRODUCT OFFERINGS 150
11.1.10 ALLOSOURCE 151
TABLE 146 ALLOSOURCE: BUSINESS OVERVIEW 151
TABLE 147 ALLOSOURCE: PRODUCT OFFERINGS 151
11.1.11 HOLOSTEM TERAPIE AVANZATE SRL 152
TABLE 148 HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW 152
TABLE 149 HOLOSTEM TERAPIE AVANZATE SRL: PRODUCT OFFERINGS 152
11.1.12 ORTHOFIX 153
TABLE 150 ORTHOFIX: BUSINESS OVERVIEW 153
FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2021) 154
TABLE 151 ORTHOFIX: PRODUCT OFFERINGS 154
11.1.13 STEMPEUTICS RESEARCH 155
TABLE 152 STEMPEUTICS RESEARCH: BUSINESS OVERVIEW 155
TABLE 153 STEMPEUTICS RESEARCH: PRODUCT OFFERINGS 155
11.1.14 REGROW BIOSCIENCES PVT LTD. 156
TABLE 154 REGROW BIOSCIENCES PVT LTD: BUSINESS OVERVIEW 156
TABLE 155 REGROW BIOSCIENCES PVT LTD: PRODUCT OFFERINGS 156
11.2 OTHER PLAYERS (PRODUCTS IN PIPELINE) 157
11.2.1 ATHERSYS, INC. 157
11.2.2 MESOBLAST LTD 157
11.2.3 BIORESTORATIVE THERAPIES, INC. 158
11.2.4 PLURISTEM INC. 158
11.2.5 BRAINSTORM CELL LIMITED. 158
11.2.6 GAMIDA CELL 159
11.2.7 VIACYTE, INC. 159
11.2.8 KANGSTEM BIOTECH 159
11.2.9 HOPE BIOSCIENCES 160
11.2.10 CELLULAR BIOMEDICINE GROUP (CBMG) 160
11.2.11 PERSONALIZED STEM CELLS 160
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 161
12.1 DISCUSSION GUIDE 161
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 163
12.3 CUSTOMIZATION OPTIONS 165
12.4 RELATED REPORTS 165
12.5 AUTHOR DETAILS 166

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（個々の器官作用薬）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（cardiovascular）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/07/05　10:26

162.17 円

175.82 円

209.73 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.